179 related articles for article (PubMed ID: 20713850)
41. The Third Intergroup Rhabdomyosarcoma Study.
Crist W; Gehan EA; Ragab AH; Dickman PS; Donaldson SS; Fryer C; Hammond D; Hays DM; Herrmann J; Heyn R
J Clin Oncol; 1995 Mar; 13(3):610-30. PubMed ID: 7884423
[TBL] [Abstract][Full Text] [Related]
42. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee.
Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D
Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650
[TBL] [Abstract][Full Text] [Related]
43. Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Mascarenhas L; Chi YY; Hingorani P; Anderson JR; Lyden ER; Rodeberg DA; Indelicato DJ; Kao SC; Dasgupta R; Spunt SL; Meyer WH; Hawkins DS
J Clin Oncol; 2019 Nov; 37(31):2866-2874. PubMed ID: 31513481
[TBL] [Abstract][Full Text] [Related]
44. Hyperfractionated radiation in children with rhabdomyosarcoma--results of an Intergroup Rhabdomyosarcoma Pilot Study.
Donaldson SS; Asmar L; Breneman J; Fryer C; Glicksman AS; Laurie F; Wharam M; Gehan EA
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):903-11. PubMed ID: 7607964
[TBL] [Abstract][Full Text] [Related]
45. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
[TBL] [Abstract][Full Text] [Related]
46. Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group.
Aye JM; Xue W; Palmer JD; Walterhouse DO; Arnold MA; Heaton TE; Venkatramani R
Pediatr Blood Cancer; 2021 Apr; 68(4):e28914. PubMed ID: 33501771
[TBL] [Abstract][Full Text] [Related]
47. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
[TBL] [Abstract][Full Text] [Related]
48. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
[TBL] [Abstract][Full Text] [Related]
49. Long-term results in children with head and neck rhabdomyosarcoma: A report from the Italian Soft Tissue Sarcoma Committee.
Affinita MC; Ferrari A; Milano GM; Scarzello G; De Leonardis F; Coccoli L; Pericoli R; Basso E; Zanetti I; Scagnellato A; Bisogno G
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115716
[TBL] [Abstract][Full Text] [Related]
50. Conservative surgical management of vaginal and vulvar pediatric rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study III.
Andrassy RJ; Hays DM; Raney RB; Wiener ES; Lawrence W; Lobe TE; Corpron CA; Smith M; Maurer HM
J Pediatr Surg; 1995 Jul; 30(7):1034-6; discussion 1036-7. PubMed ID: 7472927
[TBL] [Abstract][Full Text] [Related]
51. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Lautz TB; Xue W; Luo LY; Fair D; Qumseya A; Gao Z; Dasgupta R; Rodeberg D; Venkatramani R
Pediatr Blood Cancer; 2023 Jul; 70(7):e30357. PubMed ID: 37070563
[TBL] [Abstract][Full Text] [Related]
52. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
; Lager JJ; Lyden ER; Anderson JR; Pappo AS; Meyer WH; Breitfeld PP
J Clin Oncol; 2006 Jul; 24(21):3415-22. PubMed ID: 16849756
[TBL] [Abstract][Full Text] [Related]
53. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
[TBL] [Abstract][Full Text] [Related]
54. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Rodeberg DA; Wharam MD; Lyden ER; Stoner JA; Brown K; Wolden SL; Paidas CN; Donaldson SS; Hawkins DS; Spunt SL; Arndt CA
Int J Cancer; 2015 Jul; 137(1):204-11. PubMed ID: 25418440
[TBL] [Abstract][Full Text] [Related]
55. Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. IRS Group of the Children's Cancer Group and the Pediatric Oncology Group.
Raney RB; Asmar L; Vassilopoulou-Sellin R; Klein MJ; Donaldson SS; Green J; Heyn R; Wharam M; Glicksman AS; Gehan EA; Anderson J; Maurer HM
Med Pediatr Oncol; 1999 Oct; 33(4):362-71. PubMed ID: 10491544
[TBL] [Abstract][Full Text] [Related]
56. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study.
Wharam MD; Meza J; Anderson J; Breneman JC; Donaldson SS; Fitzgerald TJ; Michalski J; Teot LA; Wiener ES; Meyer WH
J Clin Oncol; 2004 May; 22(10):1902-8. PubMed ID: 15143083
[TBL] [Abstract][Full Text] [Related]
57. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
58. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma.
Weigel BJ; Breitfeld PP; Hawkins D; Crist WM; Baker KS
J Pediatr Hematol Oncol; 2001; 23(5):272-6. PubMed ID: 11464981
[TBL] [Abstract][Full Text] [Related]
59. Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
Abd El-Aal HH; Habib EE; Mishrif MM
J Egypt Natl Canc Inst; 2006 Mar; 18(1):51-60. PubMed ID: 17237856
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.
Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM;
J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
